Synthetic Lethality: Rising Interest from Funding Agencies

After the immense success of PARP inhibitors at ESMO 2019, synthetic lethality has become the talk of the town. From industry analysts to healthcare researchers, everyone is now interested in this emerging space. In this article, we will look at the financial backing that this domain has received over the last few years and also identify the key backers.

Over 60% of the total capital amount invested in this domain was in the last four years (2016-H1 2019

Solid Investment trend in PARP Inhibitors

Over USD 1.5 billion has been raised by companies through venture capital financing

Examples of industry stakeholders with significant funding include CStone Pharmaceuticals, eFFECTOR Therapeutics and IDEAYA Biosciences

More than 150 investors have supported diverse initiatives undertaken by small / mid-sized companies

Most Active Investors in Synthetic Lethality Market

Over time, several non-profit organizations have extended financial support to aid research efforts in this domain

Not for profit investors or Grants in Synthetic Lethality Space

With positive backing from various investment agencies and government institutes, the synthetic lethality space is well set to grow at a significant CAGR.